Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 11C | Carbon-11 |
| 5-HT7 | Serotonin (5-hydroxytryptamine) 7 receptor |
| 5HT2C | Serotonin (5-hydroxytryptamine) 2C receptor |
| AA | Atypical antipsychotic |
| AD | Alzheimer's disease |
| AE | Adverse event |
| AHA | American Heart Association |
| AHFS | American Hospital Formulary Service |
| AIMS | Abnormal Involuntary Movement Scale |
| ALT | Alanine aminotransferase |
| ANC | Absolute neutrophil count |
| ANCOVA | Analysis of covariance |
| AOM | Aripiprazole once monthly |
| AOR | Adjusted odds ratio |
| AP | Antipsychotic |
| APA | American Psychiatric Association |
| APD | Affective psychotic disorder |
| APM | Metabolic Monitoring for Children and Adolescents on Antipsychotics (HEDIS measure) |
| AST | Aspartate aminotransferase |
| ATC | Anatomical Therapeutic Chemical classification |
| AUC | Area under the plasma concentration-time curve |
| AUC0-12 | Area under the plasma concentration-time curve from 0 hours to 12 hours |
| AUC0-24 | Area under the plasma concentration-time curve from 0 hours to 24 hours |
| AUC0-inf | Area under the plasma concentration-time curve from 0 hours to infinity |
| AUC0-t | Area under the plasma concentration-time curve from 0 hours to a specified time |
| AURC | Area under the response curve |
| BARS | Barnes Akathisia Rating Scale |
| BBB | Blood-brain barrier |
| BCRP | Breast cancer resistance protein |
| BD-I | Bipolar I disorder |
| BeSt InTro | Bergen-Stavanger-Innsbruck-Trondheim study |
| BID | Twice daily |
| BMI | Body mass index |
| BPRS | Brief Psychiatric Rating Scale |
| C-SSRS | Columbia-Suicide Severity Rating Scale |
| CAHPS | Consumer Assessment of Healthcare Providers and Systems |
| CATIE | Clinical Antipsychotic Trials of Intervention Effectiveness |
| CBT | Cognitive-behavioral therapy |
| CBTp | Cognitive-behavioral therapy for psychosis |
| CC | Clinician's choice |
| CDMO | Contract development and manufacturing organization |
| CGI | Clinical Global Impressions scale |
| CGI BP | Clinical Global Impression Scale, Bipolar Version |
| CGI-S | Clinical Global Impressions-Severity of Illness scale |
| CHR-P | Clinical high risk for psychosis |
| CI | Confidence interval |
| CL/F | Apparent clearance |
| Cmax | Maximum plasma concentration |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COM | Composition of matter |
| CRCL | Creatinine clearance |
| CRI | Conditional relative importance |
| CrI | Credible interval |
| CT | Computed tomography |
| CUtLASS | Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study |
| CVD | Cardiovascular disease |
| CYP | Cytochrome P450 |
| D2, D3 | Dopamine D2 and D3 receptors |
| D2R | Dopamine D2 receptor |
| DALY | Disability-adjusted life-year |
| DCE | Discrete-choice experiment |
| DDI | Drug-drug interaction |
| DoSMD | Difference of standardized mean difference |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| DSM-5-TR | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision |
| DSM-IV | Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition |
| DSM-IV-TR | Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision |
| DUP | Duration of untreated psychosis |
| ECG | Electrocardiogram |
| ED | Emergency department |
| eGFR | Estimated glomerular filtration rate |
| EHR | Electronic health record |
| EPS | Extrapyramidal symptoms |
| EQ-5D | EuroQol 5-dimension questionnaire |
| ER | Emergency room |
| ES | Effect size |
| EUFEST | European First Episode Schizophrenia Trial |
| evLY | Equal-value life-year |
| FDA | US Food and Drug Administration |
| FDCA | Federal Food, Drug, and Cosmetic Act |
| FE | First episode |
| FEP | First-episode psychosis |
| FGA | First-generation antipsychotic |
| FPL | Federal poverty level |
| FUH | Follow-Up After Hospitalization for Mental Illness (HEDIS measure) |
| FUH-AD | Follow-Up After Hospitalization for Mental Illness: Age 18 and Older (Adult Core Set measure) |
| FUM | Follow-Up After Emergency Department Visit for Mental Illness (HEDIS measure) |
| FUM-AD | Follow-Up After Emergency Department Visit for Mental Illness: Age 18 and Older (Adult Core Set measure) |
| GBD | Global Burden of Disease study |
| GlyT1 | Glycine transporter 1 |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| H1 | Histamine H1 receptor |
| HbA1c | Glycated hemoglobin (hemoglobin A1c) |
| HCRU | Healthcare resource utilization |
| HDL | High-density lipoprotein |
| HEDIS | Healthcare Effectiveness Data and Information Set |
| hERG | Human ether-a-go-go-related gene |
| HPCMI-AD | Diabetes Care for People with Serious Mental Illness: Glycemic Status > 9.0% (Adult Core Set measure) |
| HPRL | Hyperprolactinemia |
| HR | Hazard ratio |
| HSUV | Health state utility value |
| HV | Healthy volunteer |
| I2 | I-squared statistic for heterogeneity |
| ICD-10 | International Classification of Diseases, 10th Revision |
| ICD-11 | International Classification of Diseases, 11th Revision |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| ICM | Intensive case management |
| INTEGRATE | International Guidelines for Algorithmic Treatment |
| IP | Intellectual property |
| IQR | Interquartile range |
| ISPOR | Professional Society for Health Economics and Outcomes Research (formerly International Society for Pharmacoeconomics and Outcomes Research) |
| ITT | Intention-to-treat |
| KarXT | Xanomeline-trospium |
| Ki | Inhibition constant |
| LAI | Long-acting injectable |
| LDL | Low-density lipoprotein |
| LDL-C | Low-density lipoprotein cholesterol |
| LIS | Low-income subsidy |
| LMA | Locomotor activity |
| LOS | Length of stay |
| LS | Least squares |
| LSMD | Least-squares mean difference |
| M/SUD | Mental and substance use disorder |
| M1, M4 | Muscarinic acetylcholine receptor subtypes 1 and 4 |
| mAChR | Muscarinic acetylcholine receptor |
| MAD | Multiple ascending dose |
| MADRS | Montgomery-Åsberg Depression Rating Scale |
| MAOI | Monoamine oxidase inhibitor |
| MAR | Missing at random |
| MATE1, MATE2-K | Multidrug and toxin extrusion proteins 1 and 2-K |
| MCCB | MATRICS Consensus Cognitive Battery |
| MCID | Minimum clinically important difference |
| MCS | Mental Component Summary |
| MD | Mean difference |
| MDD | Major depressive disorder |
| MDPS | Mental and Substance Use Disorders Prevalence Study |
| MetS | Metabolic syndrome |
| MH | Mental health |
| MI | Multiple imputation |
| MINI | Mini International Neuropsychiatric Interview |
| mITT | Modified intention-to-treat |
| MMRM | Mixed model for repeated measures |
| MNAR | Missing not at random |
| MRI | Magnetic resonance imaging |
| MS | Metabolic syndrome |
| MSUD | Mental and substance use disorder |
| MTD | Maximum tolerated dose |
| MY | Measurement year |
| NA | Not applicable |
| NAP | Nonaffective psychosis |
| NAPD | Non-affective psychotic disorder |
| NCEP | National Cholesterol Education Program |
| NCQA | National Committee for Quality Assurance |
| NDA | New Drug Application |
| NHANES | National Health and Nutrition Examination Survey |
| NICE | National Institute for Health and Care Excellence |
| NIMH | National Institute of Mental Health |
| NMDA | N-methyl-D-aspartate |
| NMDAR | N-methyl-D-aspartate receptor |
| NMS | Neuroleptic malignant syndrome |
| NNT | Number needed to treat |
| NNTB | Number needed to treat to benefit |
| NNTH | Number needed to treat for an additional harmful outcome |
| NOK | Norwegian kroner |
| NOS | Not otherwise specified |
| OAP | Oral antipsychotic |
| OAT1, OAT3 | Organic anion transporters 1 and 3 |
| OATP1B1, OATP1B3 | Organic anion transporting polypeptides 1B1 and 1B3 |
| OCT1, OCT2 | Organic cation transporters 1 and 2 |
| OLE | Open-label extension |
| OLZ/SAM | Olanzapine and samidorphan |
| OOP | Out-of-pocket |
| OPTiMiSE | Optimization of Treatment and Management of Schizophrenia in Europe |
| OR | Odds ratio |
| P-gp | P-glycoprotein |
| PA | Prior authorization |
| PANSS | Positive and Negative Syndrome Scale |
| PANSS-30 | 30-item Positive and Negative Syndrome Scale |
| PANSS-6 | 6-item version of the Positive and Negative Syndrome Scale |
| PCRS | Placebo-Control Reminder Script |
| PCS | Physical Component Summary |
| PCT | Patent Cooperation Treaty |
| PDUFA | Prescription Drug User Fee Act |
| PET | Positron emission tomography |
| PK | Pharmacokinetics |
| PMPM | Per member per month |
| PONV | Postoperative nausea and vomiting |
| PP | Per-protocol |
| PPP | Purchasing power parity |
| PPPM | Per patient per month |
| PPV | Positive predictive value |
| PRELAPSE | Prevention of Relapse in Schizophrenia trial |
| PRL | Prolactin |
| PSP | Personal and Social Performance scale |
| PSS | Perceived Stress Scale |
| PTE | Patent term extension |
| Q-LES-Q-SF | Quality of Life Enjoyment and Satisfaction Questionnaire Short Form |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| QoL | Quality of life |
| QT | Interval between the Q and T waves of the electrocardiogram |
| QTc | QT interval corrected for heart rate |
| QTcF | QT interval corrected for heart rate using Fridericia's formula |
| RAISE | Recovery After an Initial Schizophrenia Episode |
| RAUC | Accumulation ratio based on AUC after the first and last dose |
| RCmax | Accumulation ratio based on Cmax after the first dose and last dose |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RO | Receptor occupancy |
| RoB | Risk of bias |
| RR | Risk ratio; relative risk |
| SAA | Adherence to Antipsychotic Medications for Individuals With Schizophrenia (HEDIS measure) |
| SAA-AD | Adherence to Antipsychotic Medications for Individuals With Schizophrenia (Adult Core Set measure) |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SAMHSA | Substance Abuse and Mental Health Services Administration |
| SANS | Scale for the Assessment of Negative Symptoms |
| SAPS | Scale for the Assessment of Positive Symptoms |
| SAS | Simpson-Angus Scale |
| SCI-PANSS | Structured Clinical Interview for the Positive and Negative Syndrome Scale |
| scPCP | Subchronic phencyclidine |
| SCZ | Schizophrenia |
| SD | Standard deviation |
| SE | Standard error |
| SEM | Standard error of the mean |
| SES | Socioeconomic status |
| SG | Standard gamble |
| SGA | Second-generation antipsychotic |
| SI | Suicidal ideation |
| SMC | Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (HEDIS measure) |
| SMD | Standardized mean difference; Diabetes Monitoring for People With Diabetes and Schizophrenia (HEDIS measure) |
| SMI | Severe mental illness |
| SMR | Standardized mortality ratio |
| sNDA | Supplemental New Drug Application |
| SOC | System organ class |
| SOFAS | Social and Occupational Functioning Assessment Scale |
| SP | Suicide plan |
| SRC | Safety Review Committee |
| SRTM | Simplified reference tissue model |
| SSD | Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (HEDIS measure); schizophrenia spectrum disorder |
| SSD-AD | Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (Adult Core Set measure) |
| SSDI | Social Security Disability Insurance |
| SSI | Supplemental Security Income |
| SUD | Substance use disorder |
| SZ | Schizophrenia |
| SZ-MDD | Major depressive disorder comorbid with schizophrenia |
| t½, T1/2 | Half-life |
| TAAR1 | Trace amine-associated receptor 1 |
| TD | Tardive dyskinesia |
| TEAE | Treatment-emergent adverse event |
| Tmax | Time to reach maximum plasma concentration |
| TMS | Transcranial magnetic stimulation |
| TR | Treatment resistant |
| TRRIP | Treatment Response and Resistance in Psychosis working group |
| TRS | Treatment-resistant schizophrenia |
| UI | Uncertainty interval |
| ULN | Upper limit of normal |
| US | United States |
| USD | US dollars |
| VA/DoD | US Department of Veterans Affairs and Department of Defense |
| WHO | World Health Organization |
| XT | Xanomeline and trospium chloride |
| YLD | Years lived with disability |